ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: interstitial lung disease

New Africa / shutterstock.com

A Rheumatologist & Pulmonologist Discuss RA-ILD

Joshua Solomon, MD, & Paul F. Dellaripa, MD  |  November 14, 2021

Introduction The understanding and treatment of rheuma­toid arthritis (RA) has evolved dramatically in the past 20 years. As gains have been made in treating joint disease in RA, our understanding of the impact of extra-articular manifestations of RA, such as cardiac and lung disease—specifically interstitial lung disease (ILD)—has gradually increased. While rheumatologists increasingly appreciate the…

Filed under:ConditionsRheumatoid Arthritis Tagged with:interstitial lung disease (ILD)Pulmonary

Tips for Transitioning Patients from Pediatric to Adult Rheumatology Care

Sarah D. Bayefsky, MD, Kimberly DeQuattro, MD, & Rebecca E. Sadun, MD, PhD  |  October 14, 2021

Approximately 50% of young adult patients with childhood-onset rheumatic diseases become lost to follow-up within the first year of transferring to adult rheumatology care, mirroring the statistics of other subspecialties.1,2 One of the challenges cited most consistently by young adult patients and their families relates to differences between rheumatology care delivery in the pediatric and…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:adalimumabpsoriatic arthritisupadacitinib

2 Cases of SLE-Associated Diffuse Alveolar Hemorrage

2 Cases of SLE-Associated Diffuse Alveolar Hemorrhage

Abhimanyu Amarnani, MD, PhD, Nicole K. Zagelbaum Ward, DO, MPH, Lauren Mathias, MD, Nathan Lim, MD, Baljeet Rai, MD, Sky Wang, MD, & William Stohl, MD, PhD  |  August 12, 2021

Pulmonary manifestations in patients with systemic lupus erythematosus (SLE) include pleuritis, acute pneumonitis, interstitial lung disease, pulmonary arterial hypertension, shrinking lung syndrome and diffuse alveolar hemorrhage (DAH). DAH is a rare, but devastating, complication of SLE, with high mortality rates. The incidence of DAH in SLE ranges from 0.6% to 5.4%, but the mortality rate…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:case reportdiffuse alveolar hemorrhage

Updates in Juvenile Dermatomyositis: Pathogenesis & Patient Care

Jason Liebowitz, MD, FACR  |  July 17, 2021

Experts provided an update on juvenile dermatomyositis, discussing patient care, treatment options and the pathogenesis of disease.

Filed under:ConditionsMeeting Reports Tagged with:juvenile dermatomyositisPathogenesisPediatric RheumatologyPediatric Rheumatology SymposiumPRSYM

3 Educators Offer Lessons Learned on Rheumatology Training

Leslie Kahl, MD, Sheryl Mascarenhas, MD, & Rachel M. Wolfe, MD  |  July 15, 2021

Leslie Kahl, MD, on Coaching I have been an academic clinician-educator for my entire career and, like most of my colleagues, have been called upon to advise, mentor and coach countless trainees and junior faculty members. Unlike most clinician-educators, though, I also served as associate dean for student affairs at Washington University School of Medicine,…

Filed under:Education & Training Tagged with:FellowsFellows-in-Trainingfellowship program director

Rituximab Seems Safe & Effective for Systemic Sclerosis

Marilynn Larkin  |  June 22, 2021

NEW YORK (Reuters Health)—Rituximab seemed to be a safe and effective treatment for systemic sclerosis (SSc) in a placebo-controlled validation trial in Japan.1 “A number of studies have examined B-cell depletion therapy for systemic sclerosis, and many of them have suggested that [this] is effective in treating systemic sclerosis,” Ayumi Yoshizaki, MD, tells Reuters Health…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:rituximabsystemic sclerosis (SSc)

Case Report: Digital Ulcers & Weight Loss in a Pediatric Patient

Anusha Vuppala, MD, & Sarwat Umer, MD  |  June 13, 2021

Juvenile dermatomyositis (JDM) is a childhood form of inflammatory myopathy affecting children younger than 18 years. The diagnosis of JDM is based on characteristic clinical features of proximal muscle weakness, skin rash, elevated muscle enzymes, magnetic resonance imaging and muscle biopsy.1 Autoantibodies seen in patients with inflammatory myopathy are not only associated with particular phenotypes…

Filed under:ConditionsPediatric Conditions Tagged with:case reportinterstitial lung disease (ILD)juvenile dermatomyositisPediatric

Sarcoidosis in the Spotlight: Screening, Treatment & More Insights into Sarcoidosis

Jason Liebowitz, MD, FACR  |  June 1, 2021

An expert discussed the screening and treatment of sarcoidosis and drug-induced sarcoidosis-like reactions during the 2021 ACR State-of-the-Art Clinical Symposium.

Filed under:ConditionsMeeting Reports Tagged with:ACR State-of-the-Art Clinical SymposiumheartSarcoidosisVitamin D

Myositis Management: Clinical Trials Provide New Insights into Treatment Options

Jason Liebowitz, MD, FACR  |  May 24, 2021

Advancements in the treatment of myositis are on their way, according to Hector Chenoy, PhD, FRCP, who outlined the latest clinical trials during the 2021 ACR State-of-the-Art Clinical Symposium.

Filed under:ConditionsMeeting ReportsMyositis Tagged with:ACR State-of-the-Art Clinical Symposiumjakinibmyositis

A Mystery Case of Abdominal Masses

Vania Lin, MD, MPH, Robert Odrobina, MD, Maria A. Pletneva, MD, PhD, & Dorota Lebiedz-Odrobina, MD, RhMSUS  |  May 13, 2021

Common variable immuno­deficiency (CVID) is a common primary immuno­deficiency disease, with an estimated incidence of one per 25,000–50,000 individuals.1 The classic presen­tation includes frequent bacterial infections, secondary to dysfunctional B cell differ­entiation, impaired immunoglobulin production and diminished antibody response. The clinical presentation may be heterogenous and may include granulomatous disease as an uncommon manifestation. Granulo­matous…

Filed under:Conditions Tagged with:case reportCommon variable immunodeficiencyGranulomatosis

  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 27
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences